DOXYCYCLINE HYCLATE tablet, delayed release

Doxycycline Hyclate by

Drug Labeling and Warnings

Doxycycline Hyclate by is a Prescription medication manufactured, distributed, or labeled by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    1.1 Rickettsial Infections

    Doxycycline hyclate delayed-release tablet is indicated for treatment  Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.

    1.2 Sexually Transmitted Infections

    Doxycycline hyclate delayed-release tablet is indicated for treatment of the following sexually transmitted infections:

        Uncomplicated urethral, endocervical or rectal infections caused by Chlamydia trachomatis.

        Nongonococcal urethritis caused by Ureaplasma urealyticum.

        Lymphogranuloma venereum caused by Chlamydia trachomatis.

        Granuloma inguinale caused by Klebsiella granulomatis.

        Uncomplicated gonorrhea caused by Neisseria gonorrhoeae.

        Chancroid caused by Haemophilus ducreyi.

    1.3 Respiratory Tract Infections

    Doxycycline hyclate delayed-release tablet is indicated for treatment of the following respiratory infections:

        Respiratory tract infections caused by Mycoplasma pneumoniae.

        Psittacosis (ornithosis) caused by Chlamydophila psittaci.

        Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.

        Doxycycline is indicated for treatment of infections caused by the following micro-organisms, when bacteriological testing indicates appropriate susceptibility to the drug:

        -  Respiratory tract infections caused by Haemophilus influenzae.

        -  Respiratory tract infections caused by Klebsiella species.

        -  Upper respiratory infections caused by Streptococcus pneumonia.

    1.4 Specific Bacterial Infections

    Doxycycline hyclate delayed-release tablet is indicated for treatment of the following specific bacterial infections:

        Relapsing fever due to Borrelia recurrentis.

        Plague due to Yersinia pestis.

        Tularemia due to Francisella tularensis.

        Cholera caused by Vibrio cholerae.

        Campylobacter fetus infections caused by Campylobacter fetus.

        Brucellosis due to Brucella species (in conjunction with streptomycin).

        Bartonellosis due to Bartonella bacilliformis.

    Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.

    Doxycycline is indicated for treatment of infections caused by the following gram- negative microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:

        Escherichia coli

        Enterobacter aerogenes

        Shigella species

        Acinetobacter species

        Urinary tract infections caused by Klebsiella species.

    1.5 Ophthalmic Infections

    Doxycycline hyclate delayed-release tablet is indicated for treatment of the following ophthalmic infections:

         Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence.

         Inclusion conjunctivitis caused by Chlamydia trachomatis.

    1.6 Anthrax Including Inhalational Anthrax (Post-Exposure)

    Doxycycline hyclate delayed-release tablet is indicated for the treatment of Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.

    1.7 Alternative Treatment for Selected Infections when Penicillin is Contraindicated

    Doxycycline hyclate delayed-release tablet is indicated as an alternative treatment for the following selected infections when penicillin is contraindicated:

         Syphilis caused by Treponema pallidum.

         Yaws caused by Treponema pallidum subspecies pertenue.

         Vincent’s infection caused by Fusobacterium fusiforme.

         Actinomycosis caused by Actinomyces israelii.

         Infections caused by Clostridium species.

    1.8 Adjunctive Therapy for Acute Intestinal Amebiasis and Severe Acne

    In acute intestinal amebiasis, doxycycline hyclate delayed-release tablet  may be a useful adjunct to amebicides. 

    In severe acne, doxycycline may be useful adjunctive therapy.

    1.9 Prophylaxis of Malaria

    Doxycycline hyclate delayed-release tablet is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains [see Dosage and Administration (2.2) and Patient Counseling Information (17)].

    1.10 Usage

    To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate delayed-release tablet and other antibacterial drugs, doxycycline hyclate delayed-release tablet should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

  • 2 DOSAGE  AND ADMINISTRATION

    2.1 Important Dosage and Administration Instructions

     Doxycycline hyclate delayed-release tablet is not substitutable on a mg per mg basis with other oral doxycyclines. To avoid prescribing errors, do not substitute doxycycline hyclate delayed-release tablets for other oral doxycyclines on a mg per mg basis because of differing bioavailability.
             Do not chew or crush tablets [see Dosage and Administration (2.4)].
             The recommended dosage, frequency of administration and weight-based dosage recommendations of doxycycline hyclate delayed-release tablet differ from that of the other tetracyclines [see Dosage and Administration (2.2, 2.3, 2.4)]. Exceeding the recommended dosage may result in an increased incidence of adverse reactions.
             Administer doxycycline hyclate delayed-release tablet with an adequate amount of fluid to wash down the drug and reduce the risk of esophageal irritation and ulceration [see Adverse Reactions (6.1)].
             If gastric irritation occurs, doxycycline hyclate delayed-release tablet may be given with food or milk [see Clinical Pharmacology (12.3)].


    2.2 Switching from Doxycycline Hyclate Delayed-Release Tablets 50 mg, 75 mg, 80 mg, 100 mg, 150 mg and 200 mg to Doxycycline Hyclate Delayed-Release Tablets 60 mg and 120 mg

    When switching from doxycycline hyclate delayed-release tablets 50 mg, 75 mg, 80 mg, 100 mg, 150 mg and 200 mg to doxycycline hyclate delayed-release tablets 60 mg and 120 mg:
          A 60 mg dose of doxycycline hyclate delayed-release tablets will replace a 50 mg dose of doxycycline hyclate delayed-release tablets
          A 120 mg dose of doxycycline hyclate delayed-release tablets will replace a 100 mg dose of doxycycline hyclate delayed-release tablets


    2.3 Dosage in Adult Patients

     The usual dosage of doxycycline hyclate delayed-release tablet is 200 mg on the first day of treatment (administered 100 mg every 12 hours), followed by a maintenance dose of 100 mg daily.
     The maintenance dose may be administered as a single dose or as 50 mg every 12 hours.
     In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended.
     For certain selected specific indications, the recommended duration or dosage and duration of doxycycline hyclate delayed-release tablets 60 mg and 120 mg in adult patients are as follows:
         1. Streptococcal infections, therapy should be continued for 10 days.
         2. Uncomplicated urethral, endocervical, or rectal infection caused by C. trachomatis: 100 mg, by mouth, twice-a-day for 7 days. 
         3. Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg, by mouth, twice-a-day for 7 days. As an alternate single visit dose, administer 300 mg followed in one hour by a second 300 mg dose.
         4. Nongonococcal urethritis (NGU) caused by U. urealyticum: 100 mg, by mouth, twice-a-day for 7 days.
         5. Syphilis – early: Patients who are allergic to penicillin should be treated with doxycycline 120 mg, by mouth, twice-a-day for 2 weeks.
         6. Syphilis of more than one year’s duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg, by mouth, twice-a-day for 4 weeks.
         7. Acute epididymo-orchitis caused by N. gonorrhoeae: 100 mg, by mouth, twice-a-day for at least 10 days.
         8. Acute epididymo-orchitis caused by C. trachomatis: 100 mg, by mouth, twice-a-day for at least 10 days


    2.4 Dosage in Pediatric Patients

     For all pediatric patients weighing less than 45 kg with severe or life threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dosage of doxycycline is 2.2 mg per kg of body weight administered every 12 hours. Pediatric patients weighing 45 kg or more should receive the adult dose [see Warnings and Precautions (5.1)].

     For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule of doxycycline is 4.4 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg per kg of body weight (given as a single daily dose or divided into twice daily doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used.


    2.5 Dosage for Prophylaxis of Malaria

    For adults, the recommended dose of doxycycline hyclate delayed-release tablet is 100 mg daily. For pediatric patients 8 years of age and older, the recommended dose is 2 mg/kg administered once daily up to the adult dose. Pediatric patients weighing 45 kg or more should receive the adult dose.

    Prophylaxis should begin 1 or 2 days before travel to the malarious area. Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.

    2.6 Dosage for Inhalational Anthrax (Post-Exposure)

    For adults the recommended dosage is 100 mg of doxycycline hyclate delayed-release tablet, by mouth, twice-a-day for 60 days.


    For pediatric patients weighing less than 45 kg, the recommended dosage of doxycycline hyclate delayed-release tablet is 2.2 mg/kg of body weight, by mouth, twice-a-day for 60 days. Pediatric patients weighing 45 kg or more should receive the adult dose.

    2.7 Sprinkling the Tablet Over Applesauce

    Doxycycline hyclate delayed-release tablets may also be administered by carefully breaking up the tablet and sprinkling the tablet contents (delayed-release pellets) on a spoonful of applesauce. The delayed-release pellets must not be crushed or damaged when breaking up the tablet. Any loss of pellets in the transfer would prevent using the dose. The applesauce/doxycycline hyclate delayed-release tablets mixture should be swallowed immediately without chewing and may be followed by a glass of water if desired. The applesauce should not be hot, and it should be soft enough to be swallowed   without chewing. In the event that a prepared dose of applesauce/doxycycline hyclate delayed-release mixture cannot be taken immediately, the mixture should be discarded and not stored for later use.

  • 3 DOSAGE FORMS AND STRENGTHS

    Doxycycline hyclate delayed-release tablets USP, 75 mg having functional scoring are white, oval tablets containing yellow specks, debossed with “L241” on one side and score line on the other side. Each tablet contains specially coated pellets of doxycycline hyclate USP equivalent to 75 mg of doxycycline.


    Doxycycline hyclate delayed-release tablets USP, 100 mg having functional scoring are white, oval tablets containing yellow specks, debossed with “L242” on one side and score line on the other side. Each tablet contains specially coated pellets of doxycycline hyclate USP equivalent to 100 mg of doxycycline.


    Doxycycline hyclate delayed-release tablets USP, 150 mg having functional scoring are white, rectangular tablets containing yellow specks. Tablets have two parallel score lines on both side, debossed with “2|4|3” on one side and “|L|” on the other side. Each tablet contains specially coated pellets of doxycycline hyclate USP equivalent to 150 mg of doxycycline.


    Doxycycline hyclate delayed-release tablets USP, 200 mg having functional scoring are white, oval tablets containing yellow specks, debossed with “L594” on one side and score line on the other side. Each tablet contains specially coated pellets of doxycycline hyclate USP equivalent to 200 mg of doxycycline.



  • 4 CONTRAINDICATIONS

    Doxycycline hyclate delayed-release tablet is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Tooth Development

    The use of drugs of the tetracycline-class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use doxycycline hyclate delayed-release tablets in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies.

    5.2 Clostridiodes difficile-Associated Diarrhea

    Clostridiodes difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline hyclate delayed-release tablets, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

    C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

    If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.



    5.3 Photosensitivity

    Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

    5.4 Potential for Microbial Overgrowth

    Doxycycline hyclate delayed-release tablets may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, the antibacterial should be discontinued and appropriate therapy instituted.

    5.5 Severe Skin Reactions

    Severe skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients receiving doxycycline [see Adverse Reactions (6)]. If severe skin reactions occur, doxycycline should be discontinued immediately and appropriate therapy should be instituted.

    5.6 Intracranial Hypertension


    Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracycline including doxycycline hyclate delayed-release tablets. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Avoid concomitant use of isotretinoin and doxycycline hyclate delayed-release tablets because isotretinoin is also known to cause pseudotumor cerebri.

    Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.


    5.7 Skeletal Development

    All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.

    Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity also has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.

    5.8 Antianabolic Action

    The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.

    5.9 Malaria


    Doxycycline offers substantial but not complete suppression of the asexual blood stages of   Plasmodium strains.


    Doxycycline does not suppress P. falciparum’s sexual blood stage gametocytes. Subjects completing this prophylactic regimen may still transmit the infection to mosquitoes outside endemic areas.



    5.10 Development of Drug-Resistant Bacteria

    Prescribing doxycycline hyclate delayed-release tablets in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

    5.11 Laboratory Monitoring for Long-Term Therapy

    In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal, and hepatic studies should be performed.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trial Experience

    The safety and efficacy of doxycycline hyclate delayed-release tablets, 200 mg  as a single daily dose was evaluated in a multicenter, randomized, double-blind, active-controlled study. Doxycycline hyclate delayed-release tablets, 200 mg was given orally once-a-day for 7 days and compared to doxycycline hyclate capsules 100 mg given orally twice daily for 7 days for the treatment of men and women with uncomplicated urogenital C. trachomatis  infection.


    Adverse reactions in the Safety Population were reported by 99 (40.2%) subjects in the doxycycline hyclate delayed-release tablets, 200 mg treatment group and 132 (53.2%) subjects in the doxycycline hyclate capsules reference treatment group. Most adverse reactions were mild in intensity. The most commonly reported adverse reactions  in both treatment groups were nausea, vomiting, diarrhea, and bacterial vaginitis, Table 1.

     

     Table 1: Adverse Reactions Reported in Greater than or Equal to 2% of Subjects
    Adverse Reactions
    		Doxycycline Hyclate Delayed-Release Tablets, 200 mg
    N = 246
      n (%)
      Subjects with anyAE
    		99 (40.2)
    Nausea
    		33 (13.4)
    Vomiting
    		20 (8.1)
      Headache
    		5 (2)
    Diarrhea
    		8 (3.3)
    Abdominal  Pain Upper
    		5 (2)
    VaginitisBacterial
    		8 (3.3)
    Vulvovaginal  Mycotic Infection
    		5 (2)

    Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not always reflect the rates observed in practice.


    6.2 Postmarketing Experience

    The following adverse reactions have been identified during post-approval use of doxycycline. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate a causal relationship to drug exposure.


    Due to oral doxycycline’s virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines:


    Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, inflammatory lesions (with monilial overgrowth) in the anogenital region and pancreatitis. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Superficial discoloration of the adult permanent dentition, reversible upon drug discontinuation and professional dental cleaning has been reported. Permanent tooth discoloration and enamel hypoplasia may occur with drugs of the tetracycline class when used during tooth development [see Warnings and Precautions (5.1)]. Esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline-class. Most of these patients took medications immediately before going to bed [see Dosage and Administration (2.1)].


    Skin: Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and erythema multiforme have been reported. Photosensitivity is discussed above [see Warnings and Precautions (5.3)].


    Renal: Rise in BUN has been reported and is apparently dose-related [see Warnings and Precautions (5.8)].


    Hypersensitivity reactions: Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus, and drug reaction with eosinophilia and systemic symptoms (DRESS).


    Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.


    Intracranial Hypertension: Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracycline [see Warnings and Precautions (5.6)].


    Thyroid Gland Changes: When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function are known to occur.

  • 7 DRUG INTERACTIONS

    7.1 Anticoagulant Drugs

    Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

    7.2 Penicillin

    Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.

    7.3 Antacids and Iron Preparations

    Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.

    7.4 Oral Contraceptives

    Concurrent use of tetracycline may render oral contraceptives less effective.

    7.5 Barbiturates and Anti-Epileptics

    Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

    7.6 Penthrane

    The concurrent use of tetracycline and Penthrane® (methoxyflurane) has been reported to result in fatal renal toxicity.

    7.7 Drug/Laboratory Test Interactions

    False elevations of urinary catecholamines may occur due to interference with the fluorescence test.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no adequate and well-controlled studies on the use of doxycycline in pregnant women. The vast majority of reported experience with doxycycline during human pregnancy is short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women such as that proposed for the treatment of anthrax exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS - the Teratogen Information System - concluded that therapeutic doses during  pregnancy are unlikely to  pose  a substantial teratogenic risk (the quantity and quality of data were assessed as limited to  fair), but the   data are insufficient to state that there is no risk (see Data).1

    In the US general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.


    Clinical Considerations

    Embryo/Fetal Risk
    Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity also has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus [see Warnings and Precautions (5.1, 5.6)].

    Data

    Human Data

    A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. Sixty-three (0.19%) of the controls and 56 (0.3%) of the cases were treated with doxycycline. This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (that is, in the second and third months of gestation), with the exception of a marginal relationship with neural tube defect based on only two-exposed cases.2


    A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. All mothers reported their exposed infants were normal at 1 year of age.3


    8.2 Lactation

     

    Risk Summary

    Tetracyclines are excreted in human milk, however, the extent of absorption of tetracyclines including doxycycline, by the breastfed infant is not known. Short-term use by lactating women is not necessarily contraindicated. The effects of prolonged exposure to doxycycline in breast milk production and breast fed neonates, infants and children are unknown4. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for doxycycline and any potential adverse effects on the breast fed child from doxycycline or from the underlying maternal condition [see Warnings and Precautions (5.1, 5.6)].

      

    8.4 Pediatric Use

    Because of the effects of drugs of the tetracycline-class on tooth development and growth, use doxycycline hyclate delayed-release tablets in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly, when there are no alternative therapies [see Dosage and Administration (2.1, 2.3) and Warnings and Precautions (5.1, 5.6)].

    8.5 Geriatric Use

    Clinical studies of doxycycline hyclate delayed-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

    Doxycycline hyclate delayed-release tablets 75 mg contain 4.7 mg (0.204 mEq) of sodium.
    Doxycycline hyclate delayed-release tablets 100 mg contain 6.3 mg (0.274 mEq) of sodium.
    Doxycycline hyclate delayed-release tablets 150 mg contain 9.4 mg (0.409 mEq) of sodium.
    Doxycycline hyclate delayed-release tablets 200 mg contain 12.6 mg (0.548 mEq) of sodium.


  • 10 OVERDOSAGE

    In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.

  • 11 DESCRIPTION


      

    Doxycycline hyclate delayed-release tablets, USP contain specially coated pellets of doxycycline hyclate, USP, a tetracycline class drug synthetically derived from oxytetracycline, in a delayed-release formulation for oral administration.


    The structural formula for doxycycline hyclate, USP is:

    structure

      


    with a molecular formula of C22H24N2O8, HCl, ½ C2H6O, ½ H2O and a molecular weight of 512.9. The chemical name for doxycycline hyclate is [4S(4aR,5S,5aR,6R,12aS)] -4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-deoxonaphthacene-2- carboxamide  monohydrochloride, compound with ethyl alcohol (2:1),  monohydrate. Doxycycline hyclate, USP is a yellow to light yellow powder, freely soluble in water and in methanol; sparingly soluble in alcohol; practically insoluble in chloroform and in ether. It dissolves in aqueous solutions of alkali hydroxides and carbonates. Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form. Each tablet contains doxycycline 75 mg, 100 mg, 150 mg and 200 mg (equivalent to doxycycline hyclate 86.55 mg, 115.41 mg, 173.11 mg and 230.82). Inactive ingredients in the tablet formulation are: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, sodium chloride, povidone (K-30), hypromellose, talc, hypromellose phthalate, triethyl citrate, polyethylene glycol 6000, corn starch, lactose anhydrous, low substituted hydroxypropyl cellulose, crospovidone, colloidal silicon dioxide and magnesium stearate.


    Each doxycycline hyclate delayed-release tablets 75 mg contains 4.7 mg (0.204 mEq) of sodium, each doxycycline hyclate delayed-release tablets 100 mg contains 6.3 mg (0.274 mEq) of sodium, each doxycycline hyclate delayed-release tablets 150 mg contains 9.4 mg (0.409 mEq) of sodium and each doxycycline hyclate delayed-release tablets 200 mg contains 12.6 mg (0.548 mEq) of sodium.


     This drug product meets USP Dissolution Test 5. 

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Doxycycline is a tetracycline-class antimicrobial drug  [see Microbiology (12.4)].

    12.3 Pharmacokinetics


    Following single and multiple-dose administration of doxycycline hyclate delayed-release tablets, 200 mg to adult volunteers, average peak plasma doxycycline concentration (Cmax) was 4.6 mcg/mL and 6.3 mcg/mL, respectively with  median tmax of 3 hours; the corresponding mean plasma concentration values 24 hours after single and multiple doses were 1.5 mcg/mL and 2.3 mcg/mL, respectively.

    Absorption

    Doxycycline is virtually completely absorbed after oral administration.

    Effect of Food


    The mean Cmax and AUC0-∞ of doxycycline are 24% and 13% lower, respectively, following single dose administration of doxycycline hyclate delayed-release tablets, 100 mg with a high fat meal (including milk) compared to fasted conditions. The mean Cmax of doxycycline is 19% lower and the AUC0-∞ is unchanged following single dose administration of doxycycline hyclate delayed-release tablets, 150 mg with a high fat meal (including milk) compared to fasted conditions. The clinical significance of these decreases is unknown. Doxycycline bioavailability from doxycycline hyclate delayed-release tablets, 200 mg was not affected by food, but the incidence of nausea was higher in fasted subjects. The 200 mg tablets may be administered without regard to meals.


    When doxycycline hyclate delayed-release tablets are sprinkled over applesauce and taken with or without water, the extent of doxycycline absorption is unchanged, but the rate of absorption is increased slightly.

    Elimination

    Tetracyclines are concentrated in bile by the liver and excreted in the urine and feces at high concentrations and in a biologically active form. Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with a creatinine clearance of about 75 mL/min. This percentage may fall as low as 1 to 5%/72 hours in individuals with a creatinine clearance below 10 mL/min.


    Specific Populations

    Patients with Renal Impairment

    Studies have shown no significant difference in the serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely impaired renal function. Hemodialysis does not alter the serum half-life.


    Pediatric Patients

    Population pharmacokinetic analysis of sparse concentration-time data of doxycycline, following standard of care intravenous and oral dosing in 44 children (2 to18 years of age) showed that allometrically-scaled clearance of doxycycline in children ≥2 to ≤8 years of age (median [range] 3.58 [2.27 to 10.82] L/h/70 kg, N=11) did not differ significantly from children >8 to 18 years of age (3.27 [1.11 to 8.12] L/h/70 kg, N=33). For pediatric patients weighing ≤45 kg, body weight normalized doxycycline CL in those ≥2 to ≤8 years of age (median [range] 0.071 [0.041 to 0.202] L/kg/h, N=l0) did not differ significantly from those >8 to 18 years of age (0.081 [0.035 to 0.126] L/kg/h, N=8). In pediatric patients weighing >45 kg no clinically significant differences in body weight normalized doxycycline CL were observed between those ≥2 to ≤8 years (0.05 L/kg/h, N=l) and those >8 years of age (0.044 [0.014 to 0.121] L/kg/h, N=25). No clinically significant difference in CL differences between oral and IV were observed in the small cohort of pediatric patients who received the oral (N=l9) or IV (N=21) formulation alone.

    12.4 Microbiology

    Mechanism of Action
    Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria.

    Resistance
    Cross-resistance between tetracyclines is common.

    Antimicrobial Activity
    Doxycycline has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections [see Indications and Usage (1)].

    Gram-Negative Bacteria
    Acinetobacter species
    Bartonella bacilliformis
    Brucella     species
    Campylobacter fetus
    Enterobacter aerogenes
    Escherichia coli
    Francisella tularensis
    Haemophilus ducreyi
    Haemophilus influenzae
    Klebsiella granulomatis
    Klebsiella     species
    Neisseria gonorrhoeae
    Shigella     species
    Vibrio cholerae
    Yersinia pestis

    Gram-Positive Bacteria
    Bacillus anthracis
    Listeria monocytogenes
    Streptococcus pneumoniae

    Anaerobic Bacteria
    Clostridium species
    Fusobacterium fusiforme
    Propionibacterium acnes

    Other Bacteria
    Norcardiae and other aerobic Actinomyces species
    Borrelia recurrentis
    Chlamydophila psittaci
    Chlamydia trachomatis
    Mycoplasma pneumoniae
    Rickettsiae
    Treponema pallidum
    Treponema pallidum subspecies pertenue
    Ureaplasma urealyticum
     
    Parasites
    Balantidium coli
    Entamoeba species
    Plasmodium falciparum*

    *Doxycycline has been found to be active against the asexual erythrocytic forms of Plasmodium falciparum but not against the gametocytes of P. falciparum. The precise mechanism of action of the drug is not known.


    Susceptibility Testing
    For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see:  http://www.fda.gov/STIC.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility


    Long-term studies in animals to evaluate carcinogenic potential of doxycycline have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with the related antibacterials, oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in in vitro mammalian cell assays have been reported for related antibacterials (tetracycline, oxytetracycline).


    Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats. Effect on male fertility has not been studied.

    13.2 Animal Toxicology and/or Pharmacology

    Hyperpigmentation of the thyroid has been produced by members of the tetracycline-class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO4, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO4, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.


    Minocycline, tetracycline PO4, methacycline, doxycycline, tetracycline base, oxytetracycline HCl, and tetracycline HCl, were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet.


    Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline); in chickens (chlortetracycline); and in rats and mice (oxytetracycline). Adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline.


    Results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues.

  • 14 CLINICAL STUDIES

    This was a randomized, double-blind, active-controlled, multicenter trial which enrolled 495 subjects, between 19 to 45 years of age with a confirmed diagnosis of urogenital C. trachomatis infection less than 14 days prior to enrollment, or partner(s) of a subject with a known positive test for urogenital C. trachomatis infection.

    The primary purpose of this study was to evaluate the efficacy and safety of doxycycline hyclate delayed-release tablets, 200 mg once daily versus doxycycline hyclate capsules, 100 mg twice daily for seven days for the treatment of uncomplicated urogenital C. trachomatis infection. The primary efficacy objective was to demonstrate non-inferiority of the doxycycline hyclate delayed-release tablets, 200 mg once daily treatment regimen versus the doxycycline 100 mg twice daily treatment regimen for the indication using a negative nucleic acid amplification test (NAAT) at the test of cure visit (day 28) in the mITT population (subjects who were positive at baseline and took at least one day of study drug).


     Table 2: Primary Efficacy Outcome – Microbiological Cure of C.trachomatis at Day 28
    mITT Population 
    		Doxycycline Hyclate Delayed-Release Tablets, 200 mg once daily    Cure Rate (%) 
    		Doxycycline Hyclate Capsules, 100 mg twice daily Cure Rate (%) 
    		Difference
    (%) 
    N 
    		188
    		190
    		 
    Microbiological Cure, n (%)
    		163 (86.7)
    		171 (90)
    		-3.3%
    95% Confidence Interval for Cure Rate
    		 
    		 
    		-10.3, 3.7
  • 15 REFERENCES

    1. Friedman JM, Polifka JE. Teratogenic Effects of Drugs. A Resource for Clinicians (TERIS). Baltimore, MD: The Johns Hopkins University Press: 2000:149-195.
    2. Cziezel AE and Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 1997; 89: 524-528.
    3. Horne HW Jr. and Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. Int J Fertil 1980; 25:  315-317.
    4. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); [Last Revision Date 2015 March 10; cited 2016 Jan]. Doxycycline; LactMed Record Number: 100; [about 3 screens]. Available from: http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm.
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Doxycycline hyclate delayed-release tablets USP, 75 mg having functional scoring are white, oval tablets containing yellow specks, debossed with “L241” on one side and score line on the other side. Each tablet contains specially coated pellets of doxycycline hyclate USP equivalent to 75 mg of doxycycline.

    NDC: 62332-481-60    bottle of 60 tablets

    NDC: 62332-481-31    bottle of 100 tablets

    NDC: 62332-481-91    bottle of 1000 tablets


    Doxycycline hyclate delayed-release tablets USP, 100 mg having functional scoring are white, oval tablets containing yellow specks, debossed with “L242” on one side and score line on the other side.Each tablet contains specially coated pellets of doxycycline hyclate USP equivalent to 100 mg of doxycycline.

    NDC: 62332-482-60    bottle of 60 tablets

    NDC: 62332-482-31    bottle of 100 tablets

    NDC: 62332-482-91    bottle of 1000 tablets


    Doxycycline hyclate delayed-release tablets USP, 150 mg having functional scoring are white, rectangular tablets containing yellow specks. Tablets have two parallel score lines on both side, debossed with “2|4|3” on one side and “|L|” on the other side. Each tablet contains specially coated pellets of doxycycline hyclate USP equivalent to 150 mg of doxycycline.

    NDC: 62332-483-30    bottle of 30 tablets

    NDC: 62332-483-60    bottle of 60 tablets

    NDC: 62332-483-31    bottle of 100 tablets

    NDC: 62332-483-71    bottle of 500 tablets


    Doxycycline hyclate delayed-release tablets USP, 200 mg having functional scoring are white, oval tablets containing yellow specks, debossed with “L594” on one side and score line on the other side. Each tablet contains specially coated pellets of doxycycline hyclate USP equivalent to 200 mg of doxycycline.

    NDC: 62332-484-30  bottle of 30 tablets

    NDC: 62332-484-60    bottle of 60 tablets

    NDC: 62332-484-31    bottle of 100 tablets

    NDC: 62332-484-71    bottle of 500 tablets


    Store at 25° C (77° F); excursions permitted to 15° to 30° C (59° to 86° F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container (USP).

  • 17 PATIENT COUNSELING INFORMATION


    Advise patients taking doxycycline for malaria prophylaxis:
     that no present-day antimalarial agent, including doxycycline, guarantees protection against malaria. 
     to avoid being bitten by mosquitoes by using personal protective measures that help avoid contact with mosquitoes, especially from dusk to dawn (for example, staying in well-screened areas, using mosquito nets, covering the body with clothing, and using an effective insect repellent).
     that doxycycline prophylaxis:

          - should begin 1 to 2 days before travel to the malarious area,

          - should be continued daily while in the malarious area and after leaving the malarious area,  

          - should be continued for 4 further weeks to avoid development of malaria after returning from an endemic area,

         - should not exceed 4 months.

    Advise all patients taking doxycycline:

     to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if phototoxicity (for example, skin eruptions, etc.) occurs. Sunscreen or sunblock should be considered [see Warnings and Precautions (5.3)].
     to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration [see Adverse Reactions (6.1)].
     that the absorption of tetracyclines is reduced when taken with foods, especially those that contain calcium. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk [see Drug Interactions (7.3)].
     that the absorption of tetracyclines is reduced when taken with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations [see Drug Interactions (7.3)]. 
     that the use of doxycycline might increase the incidence of vaginal candidiasis.

    Advise patients that diarrhea is a common problem caused by antibacterials which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of antibacterial. If this occurs, patients should contact their physician as soon as possible.

    Patients should be counseled that antibacterial drugs including doxycycline hyclate delayed-release tablets should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When doxycycline hyclate delayed-release tablets is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by doxycycline hyclate delayed-release tablets or other antibacterial drugs in the future.

    17.1 Instructions for Breaking the 150 mg Doxycycline Hyclate Delayed-Release Dual-Scored Tablet

    The tablet is marked with separation lines (score lines) and may be broken at these score lines to provide any of the following doses.

    150 mg treatment (the entire tablet is taken)
    doxycycline-full-150mg tablet.jpg
    100 mg  treatment (two thirds of the tablet or two 50 mg  tablet segments are taken)
    doxycycline-two-third tablet.jpg

    50 mg  treatment (one third of the tablet is  taken)
    doxycycline-one-third tablet.jpg

    To break the tablet, the tablet is held between the thumbs and index fingers close to the appropriate score line. Then, with the score line facing the patient, enough pressure is applied to snap the tablet segments apart (segments that do not break along the score line should not be used).

  • FDA-Approved Patient Labeling

    Doxycycline hyclate delayed-release tablets 75 mg, 100 mg, 150 mg and 200 mg

    Instructions for breaking the 150 mg doxycycline hyclate delayed-release dual-scored tablet

    Your doctor may find it necessary to adjust your dosage of doxycycline hyclate delayed-release tablets to obtain the proper treatment response. The tablet is marked with separation lines (score lines) and may be broken at these score lines to provide any of the following doses. If your doctor prescribed:

     150 mg  treatment (take the entire tablet)
    doxycycline-full-150mg tablet.jpg
     100 mg  treatment (take  two thirds of the tablet or two 50 mg tablet segments)
    doxycycline-two-third tablet.jpg
     50 mg treatment (take  one third of the tablet)
    doxycycline-one-third tablet.jpg

    To break the tablet, hold the tablet between your thumbs and index fingers close to the   appropriate score line. Then, with the score line facing you, apply enough pressure to snap the tablet segments apart (do not use segments that do not break along the score line).

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    For more information call Alembic Pharmaceuticals Limited at 1-866-210-9797.

    Brands listed are the trademarks of their respective owners.

    Rx only

    Manufactured by:
    Alembic Pharmaceuticals Limited
    (Formulation Division),
    Panelav 389350, Gujarat, India

    Manufactured for:
    Alembic Pharmaceuticals, Inc.

    Bedminster, NJ 07921, USA


    Revised: 03/2023

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-75 mg

    NDC: 62332-481-60
    Doxycycline Hyclate
    Delayed-Release
    Tablets, USP
    75 mg
    Do not chew or crush tablets.
    Rx only
    60 Tablets
    Alembic

    60tablets

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-100 mg

    NDC: 62332-482-60
    Doxycycline Hyclate
    Delayed-Release
    Tablets, USP
    100 mg
    Do not chew or crush tablets.
    Rx only
    60 Tablets
    Alembic

    60tablets

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-150 mg

    NDC: 62332-483-60
    Doxycycline
    Hyclate
    Delayed-Release
    Tablets, USP
    150 mg
    Do not chew or crush tablets.
    Rx only
    60 Tablets
    Alembic

    60tablets

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-200 mg

    NDC: 62332-484-60
    Doxycycline
    Hyclate
    Delayed-Release
    Tablets, USP
    200 mg
    Do not chew or crush tablets.
    Rx only
    60 Tablets
    Alembic

    60tablets

  • INGREDIENTS AND APPEARANCE
    DOXYCYCLINE HYCLATE 
    doxycycline hyclate tablet, delayed release
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 62332-481
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DOXYCYCLINE HYCLATE (UNII: 19XTS3T51U) (DOXYCYCLINE ANHYDROUS - UNII:334895S862) DOXYCYCLINE ANHYDROUS75 mg
    Inactive Ingredients
    Ingredient NameStrength
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    POVIDONE K30 (UNII: U725QWY32X)  
    HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)  
    TALC (UNII: 7SEV7J4R1U)  
    TRIETHYL CITRATE (UNII: 8Z96QXD6UM)  
    POLYETHYLENE GLYCOL 6000 (UNII: 30IQX730WE)  
    HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED (UNII: 2165RE0K14)  
    CROSPOVIDONE (UNII: 68401960MK)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST) (UNII: 87Y6436BKR)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)  
    Product Characteristics
    ColorWHITE (containing yellow specks) Score2 pieces
    ShapeOVALSize13mm
    FlavorImprint Code L241
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 62332-481-6060 in 1 BOTTLE; Type 0: Not a Combination Product01/04/2022
    2NDC: 62332-481-31100 in 1 BOTTLE; Type 0: Not a Combination Product01/04/2022
    3NDC: 62332-481-911000 in 1 BOTTLE; Type 0: Not a Combination Product01/04/2022
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21307501/04/2022
    DOXYCYCLINE HYCLATE 
    doxycycline hyclate tablet, delayed release
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 62332-482
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DOXYCYCLINE HYCLATE (UNII: 19XTS3T51U) (DOXYCYCLINE ANHYDROUS - UNII:334895S862) DOXYCYCLINE ANHYDROUS100 mg
    Inactive Ingredients
    Ingredient NameStrength
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    POVIDONE K30 (UNII: U725QWY32X)  
    HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)  
    TALC (UNII: 7SEV7J4R1U)  
    TRIETHYL CITRATE (UNII: 8Z96QXD6UM)  
    POLYETHYLENE GLYCOL 6000 (UNII: 30IQX730WE)  
    HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED (UNII: 2165RE0K14)  
    CROSPOVIDONE (UNII: 68401960MK)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST) (UNII: 87Y6436BKR)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)  
    Product Characteristics
    ColorWHITE (containing yellow specks) Score2 pieces
    ShapeOVALSize16mm
    FlavorImprint Code L242
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 62332-482-6060 in 1 BOTTLE; Type 0: Not a Combination Product01/04/2022
    2NDC: 62332-482-31100 in 1 BOTTLE; Type 0: Not a Combination Product01/04/2022
    3NDC: 62332-482-911000 in 1 BOTTLE; Type 0: Not a Combination Product01/04/2022
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21307501/04/2022
    DOXYCYCLINE HYCLATE 
    doxycycline hyclate tablet, delayed release
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 62332-483
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DOXYCYCLINE HYCLATE (UNII: 19XTS3T51U) (DOXYCYCLINE ANHYDROUS - UNII:334895S862) DOXYCYCLINE ANHYDROUS150 mg
    Inactive Ingredients
    Ingredient NameStrength
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    POVIDONE K30 (UNII: U725QWY32X)  
    HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)  
    TALC (UNII: 7SEV7J4R1U)  
    TRIETHYL CITRATE (UNII: 8Z96QXD6UM)  
    POLYETHYLENE GLYCOL 6000 (UNII: 30IQX730WE)  
    HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED (UNII: 2165RE0K14)  
    CROSPOVIDONE (UNII: 68401960MK)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST) (UNII: 87Y6436BKR)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    Product Characteristics
    ColorWHITE (containing yellow specks) Score3 pieces
    ShapeRECTANGLESize18mm
    FlavorImprint Code 2;4;3;L
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 62332-483-6060 in 1 BOTTLE; Type 0: Not a Combination Product01/04/2022
    2NDC: 62332-483-31100 in 1 BOTTLE; Type 0: Not a Combination Product01/04/2022
    3NDC: 62332-483-71500 in 1 BOTTLE; Type 0: Not a Combination Product01/04/2022
    4NDC: 62332-483-3030 in 1 BOTTLE; Type 0: Not a Combination Product03/07/2023
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21307501/04/2022
    DOXYCYCLINE HYCLATE 
    doxycycline hyclate tablet, delayed release
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 62332-484
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DOXYCYCLINE HYCLATE (UNII: 19XTS3T51U) (DOXYCYCLINE ANHYDROUS - UNII:334895S862) DOXYCYCLINE ANHYDROUS200 mg
    Inactive Ingredients
    Ingredient NameStrength
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    POVIDONE K30 (UNII: U725QWY32X)  
    HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)  
    TALC (UNII: 7SEV7J4R1U)  
    TRIETHYL CITRATE (UNII: 8Z96QXD6UM)  
    POLYETHYLENE GLYCOL 6000 (UNII: 30IQX730WE)  
    HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED (UNII: 2165RE0K14)  
    CROSPOVIDONE (UNII: 68401960MK)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST) (UNII: 87Y6436BKR)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)  
    Product Characteristics
    ColorWHITE (containing yellow specks) Score2 pieces
    ShapeOVALSize19mm
    FlavorImprint Code L594
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 62332-484-6060 in 1 BOTTLE; Type 0: Not a Combination Product01/04/2022
    2NDC: 62332-484-31100 in 1 BOTTLE; Type 0: Not a Combination Product01/04/2022
    3NDC: 62332-484-71500 in 1 BOTTLE; Type 0: Not a Combination Product01/04/2022
    4NDC: 62332-484-3030 in 1 BOTTLE; Type 0: Not a Combination Product10/15/2022
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21307501/04/2022
    Labeler - Alembic Pharmaceuticals Inc. (079288842)
    Establishment
    NameAddressID/FEIBusiness Operations
    Alembic Pharmaceuticals Limited650574671MANUFACTURE(62332-481, 62332-482, 62332-483, 62332-484)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.